Interleukin-18 and outcome after allogeneic stem cell transplantation: A retrospective cohort study

[1]  Rajiv Kumar,et al.  Asymmetric dimethylarginine serum levels are associated with early mortality after allogeneic stem cell transplantation , 2018, Haematologica.

[2]  G. Kaplanski.  Interleukin‐18: Biological properties and role in disease pathogenesis , 2017, Immunological reviews.

[3]  B. Blazar,et al.  Acute Graft-versus-Host Disease - Biologic Process, Prevention, and Therapy. , 2017, The New England journal of medicine.

[4]  F. Spertini,et al.  Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still’s disease , 2017, Annals of the rheumatic diseases.

[5]  M. Taniwaki,et al.  A Novel Diagnostic and Prognostic Biomarker Panel for Endothelial Cell Damage-Related Complications in Allogeneic Transplantation. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[6]  Hui Zhang,et al.  Detection of Serum Interleukin‐6/10/18 Levels in Sepsis and Its Clinical Significance , 2016, Journal of clinical laboratory analysis.

[7]  M. Rekhter,et al.  PKC-β activation inhibits IL-18-binding protein causing endothelial dysfunction and diabetic atherosclerosis. , 2015, Cardiovascular Research.

[8]  C. Dinarello,et al.  Interleukin-18 and IL-18 Binding Protein , 2013, Front. Immunol..

[9]  Thomas A Gerds,et al.  Estimating a time‐dependent concordance index for survival prediction models with covariate dependent censoring , 2013, Statistics in medicine.

[10]  P. Migliorini,et al.  Free IL-18 and IL-33 cytokines in chronic spontaneous urticaria. , 2013, Cytokine.

[11]  W. Hiddemann,et al.  Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial. , 2012, The Lancet. Oncology.

[12]  M. Díaz-Ricart,et al.  Combining allografting with mTOR inhibitors for metastatic renal cell cancer , 2011, Bone Marrow Transplantation.

[13]  T. Luft,et al.  Steroid-refractory GVHD: T-cell attack within a vulnerable endothelial system. , 2011, Blood.

[14]  F. Hu,et al.  Genome-Wide Association Study Identifies Variants at the IL18-BCO2 Locus Associated With Interleukin-18 Levels , 2010, Arteriosclerosis, thrombosis, and vascular biology.

[15]  B. Sandmaier,et al.  Defining the intensity of conditioning regimens: working definitions. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[16]  R. Brand,et al.  Risk score for outcome after allogeneic hematopoietic stem cell transplantation , 2009, Cancer.

[17]  F. Veglia,et al.  Markers of inflammation, thrombosis and endothelial activation correlate with carotid IMT regression in stable coronary disease after atorvastatin treatment. , 2009, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[18]  M. Schumacher,et al.  Consistent Estimation of the Expected Brier Score in General Survival Models with Right‐Censored Event Times , 2006, Biometrical journal. Biometrische Zeitschrift.

[19]  J. Beilby,et al.  Elevated Interleukin-18 Levels Are Associated With the Metabolic Syndrome Independent of Obesity and Insulin Resistance , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[20]  M. Sorror,et al.  Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. , 2005, Blood.

[21]  S. Clouthier,et al.  Paradoxical effects of interleukin-18 on the severity of acute graft-versus-host disease mediated by CD4+ and CD8+ T-cell subsets after experimental allogeneic bone marrow transplantation. , 2004, Blood.

[22]  K. Kliche,et al.  Increase of interleukin-18 serum levels after engraftment correlates with acute graft-versus-host disease in allogeneic peripheral blood stem cell transplantation , 2004, Journal of Cancer Research and Clinical Oncology.

[23]  G. Fantuzzi,et al.  Interleukin-18 and host defense against infection. , 2003, The Journal of infectious diseases.

[24]  J. Ferrara,et al.  Role of interleukin-18 in acute graft-vs-host disease. , 2003, The Journal of laboratory and clinical medicine.

[25]  K. Ulm,et al.  DIFFERENTIAL REGULATION OF SYSTEMIC IL-18 AND IL-12 RELEASE DURING POSTOPERATIVE SEPSIS: HIGH SERUM IL-18 AS AN EARLY PREDICTIVE INDICATOR OF LETHAL OUTCOME , 2002, Shock.

[26]  D. Giugliano,et al.  Weight loss reduces interleukin-18 levels in obese women. , 2002, The Journal of clinical endocrinology and metabolism.

[27]  F. Cambien,et al.  Interleukin-18 Is a Strong Predictor of Cardiovascular Death in Stable and Unstable Angina , 2002, Circulation.

[28]  C. Dinarello,et al.  Interleukin-18 binding protein in acute graft versus host disease and engraftment following allogeneic peripheral blood stem cell transplants. , 2001, Journal of hematotherapy & stem cell research.

[29]  T. Masaoka,et al.  Serum levels of soluble IL-2 receptor, IL-12, IL-18, and IFN-γ in patients with acute graft-versus-host disease after allogeneic bone marrow transplantation , 2000 .

[30]  H. Okamura,et al.  Elevated interleukin (IL)‐18 levels during acute graft‐versus‐host disease after allogeneic bone marrow transplantation , 2000, British journal of haematology.

[31]  P. Barie,et al.  Elevation of IL-18 in Human Sepsis , 2000, Journal of Clinical Immunology.

[32]  S. Chan,et al.  Kinetics of interferon‐γ secretion and its regulatory factors in the early phase of acute graft‐versus‐host disease , 1999, Immunology.

[33]  G. Hill,et al.  The role of cytokines in acute graft-versus-host disease. , 1997, Cytokines, cellular & molecular therapy.

[34]  S. Bandinelli,et al.  An interleukin-18 polymorphism is associated with reduced serum concentrations and better physical functioning in older people. , 2007, The journals of gerontology. Series A, Biological sciences and medical sciences.

[35]  A. Ghavamzadeh,et al.  Effect of IL-18 and sIL2R on aGVHD occurrence after hematopoietic stem cell transplantation in some Iranian patients. , 2006, Transplant immunology.